<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210739</url>
  </required_header>
  <id_info>
    <org_study_id>chronic prostatitis</org_study_id>
    <nct_id>NCT04210739</nct_id>
  </id_info>
  <brief_title>Chronic Non Bacterial Prostatitis: a Trial of TRUS Guided Injection of Betamethason</brief_title>
  <official_title>Managment of Refractory Cases of Chronic Non Bacterial Prostatitis by TRUS Guided Injection of Betamethason</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRUS guided injection of long acting corticosteroids in chronic non bacterial prostatitis
      patients who failed to response to medical treamtment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      chronic non bacterial prostatitis is usually due to congestion combined with severe
      inflammatory process of the prostate, it is usually a recurrent bothersome problem, so
      patients who fail to response to classic medical treatment are expected to benefit from a
      strong anti inflammatory injection like betamethasone, which has strong anti inflammatory
      plus anti oedematous properties so limitation of this inflammatory process across the
      prostate is expected to relieve the patients symptoms
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>chronic non bacterial prostatitis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing IPSS before and after injection.</measure>
    <time_frame>evaluation over 3 months after injection</time_frame>
    <description>Questionnaire comparing IPSS (international prostatic symptom score) before and after injection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Non Bacterial Prostatitis</condition>
  <arm_group>
    <arm_group_label>trus guided betamethason injection arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethason Sodium Phosphate</intervention_name>
    <description>Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound</description>
    <arm_group_label>trus guided betamethason injection arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic non bacterial prostatitis who failed medical treatment

        Exclusion Criteria:

          -  chronic bacterial prostatitis patients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Abozamel</investigator_full_name>
    <investigator_title>Doctor Lecturer in Urology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

